Page last updated: 2024-10-17

n(1)-methylnicotinamide and Chronic Kidney Diseases

n(1)-methylnicotinamide has been researched along with Chronic Kidney Diseases in 2 studies

N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Zhang, W1
Rong, G1
Gu, J1
Fan, C1
Guo, T1
Jiang, T1
Deng, W1
Xie, J1
Su, Z1
Yu, Q1
Mai, J1
Zheng, R1
Chen, X1
Tang, X1
Zhang, J1
Kalantari, S1
Chashmniam, S1
Nafar, M1
Samavat, S1
Rezaie, D1
Dalili, N1

Other Studies

2 other studies available for n(1)-methylnicotinamide and Chronic Kidney Diseases

ArticleYear
Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2022, Volume: 36, Issue:3

    Topics: Animals; Cells, Cultured; Fibrosis; Kidney; Male; Mice; Mice, Inbred C57BL; Niacinamide; Nicotinamid

2022
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
    Omics : a journal of integrative biology, 2020, Volume: 24, Issue:3

    Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies

2020